Peripheral intravenous norepinephrine

Phase 3Small molecule

Peripheral intravenous norepinephrine is one of 25 small molecule programs targeting Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypertensionActive, not recruiting

HypertensionPhase 3

Active, not recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

Apresoline

Novartis

Preclinical

7 2

Zebeta

Teva

Preclinical

6 3

Edarbi

Takeda

Preclinical

4 4

Peripheral intravenous norepinephrine

UUniversity Hospital, Bordeaux

Phase 3

1 5

Alphagan

Winrevair

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

2 8

Disalcid

JJoslin Diabetes Center

Preclinical

1 9

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Hypertension

NCT06059144

Clinical

Trials by Indication[1]

Hypertension1 trial

Induced Hypertension in Acute PRogrESsive Perforating Artery Stroke Using Peripheral Dilute noREpinephrine

Recruiting·UUniversity Hospital, Bordeaux·Phase 3·NCT06059144·358 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Peripheral intravenous norepinephrine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Peripheral intravenous norepinephrine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Peripheral intravenous norepinephrine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Bordeaux company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Bordeaux

Peripheral intravenous norepinephrine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Hypertension1 trial

References

Drug Info

Quick Facts

Related News